Savara (SVRA) Current Leases (2016 - 2018)

Savara (SVRA) reported Current Leases of $41000.0 for Q4 2018, down 84.53% year-over-year from $265000.0 in Q4 2017, and down 87.11% quarter-over-quarter from $318000.0 in Q3 2018.

Savara (SVRA) Current Leases (2016 - 2018) Analysis & Trends

Savara (SVRA) has 3 years of Current Leases data on file, last reported at $41000.0 in Q4 2018.

  • Current Leases for Q4 2018 came in at $41000.0, down 84.53% year-over-year; the trailing twelve-month figure through Dec 2018 was $41000.0 (down 84.53% YoY), and the FY2018 annual result was $41000.0, down 84.53% from the prior year.
  • Current Leases slipped to $41000.0 in Q4 2018 per SVRA's latest filing, from $318000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $719000.0 in Q2 2017 and troughed at $21000.0 in Q1 2018.
  • A 3-year average of $298625.0 and a median of $291500.0 in 2017 frame the typical range for Current Leases.
  • On a YoY basis, Current Leases climbed as much as 20.0% in 2018 and fell as far as 84.53% in 2018.
  • A 3-year view of Current Leases shows it stood at $442000.0 in 2016, then slumped by 40.05% to $265000.0 in 2017, then plunged by 84.53% to $41000.0 in 2018.
  • Business Quant data shows SVRA's Current Leases at $41000.0 in Q4 2018, $318000.0 in Q3 2018, and $318000.0 in Q2 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 83,991.00
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 7.40 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Savara 1.39 Bn 1.39 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2018 41,000.00
Sep 30, 2018 318,000.00
Jun 30, 2018 318,000.00
Mar 31, 2018 21,000.00
Dec 31, 2017 265,000.00
Sep 30, 2017 265,000.00
Jun 30, 2017 719,000.00
Dec 31, 2016 442,000.00